BACE1-AS is upregulated in plasma of AD patients, suggesting that it may serve as a potential blood-based biomarker for AD development (Feng et al., 2018[37]; Fotuhi et al., 2019[38]). This evidence concerns the gene BACE1 and Alzheimer disease.